Servier buys Shire's oncology unit for $2.4B in the run-up to Takeda's final buyout offer — if it makes one
If Takeda comes knocking on Shire’s door for what would be the largest acquisition in 2018, it won’t get the whole package it was angling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
